Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
PHASE1CompletedINTERVENTIONAL
Enrollment
12
Participants
Timeline
Start Date
January 7, 2019
Primary Completion Date
August 20, 2019
Study Completion Date
August 20, 2019
Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL
RC28-E
RC28-E intravitreous injection 50ul
Trial Locations (1)
100730
Beijing Tongren Hospital .Cmu, Beijing
All Listed Sponsors
lead
RemeGen Co., Ltd.
INDUSTRY
NCT03777254 - Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter